5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial

International Journal of Cancer

Volumn 138, Issue 12, 2016, Pages 2820-2828

  Murtola, Teemu J ^a,b   Karppa, Elina K ^a   Taari, Kimmo ^c   Talala, Kirsi ^d   Tammela, Teuvo Lj ^a,b   Auvinen, Anssi ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

Author keywords

5 alpha reductase inhibitors; adrenergic alpha blockers; prostate cancer; survival

Indexed keywords

DUTASTERIDE; FINASTERIDE; ANTINEOPLASTIC AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; KAPLAN MEIER METHOD; MASS SCREENING; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANTINEOPLASTIC AGENTS; EARLY DETECTION OF CANCER; FINLAND; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS;

EID: 84958280309     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30017     Document Type: Article

References (17)

1. Marberger M., Drug insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Nat Clin Pract Urol 2006; 3: 495-503.
2. Thompson IM, Goodman PJ, Tangen CM, et al., The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
3. Andriole GL, Bostwick D, Brawley OW, et al., The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011; 185: 126-31.
4. Murtola TJ, Tammela TLJ, Määttänen L, et al., Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009; 101: 843-8.
5. Thompson IM, Jr, Goodman PJ, Tangen CM, et al., Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013; 369: 603-10.
6. Kjellman A, Friis S, Granath F, et al., Treatment with finasteride and prostate cancer survival. Scand J Urol 2013; 47: 265-71.
7. Preston MA, Wilson KM, Markt SC, et al., 5α-reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 2014; 174: 1301-07.
8. Azoulay L, Eberg M, Benayoun S, et al., 5α-reductase inhibitors and the risk of cancer-related mortality in men with prostate cancer. JAMA Oncol 2015; 1: 314-20.
9. Kilpeläinen TP, Tammela TL, Malila N, et al., Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst 2013; 105: 719-25.
10. Martikainen J, Rajaniemi S., Drug reimbursement systems in EU Member States, Iceland and Norway. Helsinki: The Social Insurance Institution, Finland, Social security and health reports 2002.
11. US Food and Drug Administration, Oncologic Drugs Advisory Committee, December 1, 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM237498.pdf. (Accessed on May 20, 2015).
12. Pinsky P, Parnes H, Ford L., Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res (Phila) 2008; 1: 182-6.
13. Lucia MS, Darke AK, Goodman PJ, et al., Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) 2008; 1: 167-73.
14. Thompson IM, Chi C, Ankerst DP, et al., Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128-33.
15. Murtola TJ, Kujala PM, Tammela TLJ., High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5alpha-reductase inhibitors and alpha-blockers. The Prostate 2013; 73: 923-31.
16. Orsted DD, Bojesen SE, Nielsen SF, et al., Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 2011; 60: 691-98.
17. Suissa S, Azoulay L., Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-73.